Medpace Holdings, Inc. announced the departure of Board of Directors member Ashley M. Keating, effective June 30, 2024. Her resignation occurred without disagreement on company operations, policies, or practices. The company's Board, following the independent directors' recommendation, elected Dr. Dani S. Zander as the new Class III director effective July 1, 2024. Dr. Zander will serve until the 2025 Annual Meeting of Stockholders. She also joins the Nominating and Governance Committee. Dr. Zander is recognized in the fields of pulmonary pathology and molecular pathology, having previously held leadership and academic positions at the University of Cincinnati and other notable institutions. She brings to Medpace significant scholarly and leadership experience, including publications, editorial roles, and teaching awards. Dr. Zander received equity in the form of stock options as part of the company's standard compensation for non-employee directors.
Names mentioned: - Medpace Holdings, Inc. - Ashley M. Keating - Dr. Dani S. Zander - University of Cincinnati - Association of Pathology Chairs (APC) - American Journal of Pathology - New York University - University of Florida - Stephen P. Ewald